Background:　Blepharoptosis　is　one　of　the　most　common　eyelid　disorders　in　clinical　ophthalmology.　Previous　evidence　on　drug-related　blepharoptosis　limited　to　case　reports.Objectives:　This　study　aims　to　systematically　evaluate　the　disproportionality　signals　of　drugs　associated　with　blepharoptosis　using　large-scale　real-world　data　from　the　US　FDA　Adverse　Event　Reporting　System　(FAERS).Design:　A　retrospective　disproportionality　analysis　was　conducted　based　on　the　FAERS　database.Methods:　A　total　of　21,838,627　reports　from　the　FAERS　database,　spanning　2004　to　2024,　were　included,　with　19,541,994　reports　retained　after　deduplication.　Disproportionality　analysis　methods　including　reporting　odds　ratio,　proportional　reporting　ratio,　Bayesian　confidence　propagation　neural　network,　and　multi-item　gamma　Poisson　shrinker　were　employed　to　detect　positive　signals.　The　therapeutic　purposes　of　the　drugs,　drug-related　reporting　patterns,　drug　signals　strength,　and　onset　times　of　adverse　reactions　were　comprehensively　assessed.Results:　A　total　of　9324　cases　of　blepharoptosis　were　confirmed,　involving　20　identified　with　significant　signals.　They　primarily　include　antineoplastic　and　immunomodulating　agents,　sensory　organ　drugs,　and　neuropsychiatric　drugs.　Eleven　drugs　had　previously　been　reported　to　be　associated　with　blepharoptosis,　while　9　were　newly　identified.　Botulinum　toxin　A,　ravulizumab,　and　latanoprost　were　found　to　exhibit　the　strongest　signals.　Neuropsychiatric　drugs　(e.g.,　lidocaine)　had　a　median　onset　time　of　1-9　days,　while　antineoplastic　and　immunomodulating　agents　(e.g.,　ravulizumab)　had　a　median　onset　time　of　164-912　days.　Avelumab　and　rosuvastatin　showed　stronger　signals　for　elderly　males,　while　botulinum　toxin　A　and　bupivacaine　were　more　significant　for　younger　females.Conclusion:　This　study　validates　known　associations　such　as　immune　checkpoint　inhibitors　and　neuroregulatory　agents,　and　identifies　drug-related　signals.　There　are　significant　differences　in　the　onset　times　of　adverse　reactions　across　drug　categories,　suggesting　the　need　for　targeted　monitoring.